OpenPayer

This revision is the Cigna EN0383 coverage policy for Transcranial Magnetic Stimulation (TMS) effective 2026-03-15. The document consolidates detailed background, device FDA clearances, and an expansive literature review covering multiple TMS modalities (e.g., rTMS, dTMS, theta burst stimulation TBS, accelerated TMS aTMS, priming pTMS, and navigated TMS nTMS). It highlights recent FDA 510(k) actions and device indications referenced in the policy text (for example, Brainsway Deep TMS System iTBS clearance and Magnus Neuromodulation System with SAINT Technology 510(k) clearance). The revision explicitly enumerates indications and non‑indications for which TMS has not been demonstrated effective in peer‑reviewed literature or lacks FDA approval.

The policy text emphasizes the heterogeneity of evidence across modalities and conditions and documents specific methodological limitations that informed coverage considerations: small sample sizes, short follow‑up, variability in stimulation parameters, and inconsistent outcome measures. It also incorporates device‑specific FDA language (e.g., Brainsway DTMS for short‑term smoking cessation; TBS‑cleared systems for treatment‑resistant depression) as the regulatory context for clinical evidence.

The policy scope covers TMS use for unipolar major depressive disorder, obsessive‑compulsive disorder, and other psychiatric and neurological conditions in adults and adolescents. It differentiates common TMS methods (rTMS as surface cortical stimulation with figure‑of‑eight coils and dTMS using H‑coils/Hesel‑coils to reach deeper targets), and describes modality‑specific technical parameters that affect clinical effects (frequency, waveform, intensity, motor threshold determination).

Cigna's document explicitly notes FDA clearances tied to clinical indications: Brainsway Deep TMS System (including iTBS protocol) has 510(k) clearance for depressive episodes in adult patients with MDD who failed prior antidepressant treatment; Brainsway H4/HADD‑coil devices have labeling for short‑term smoking cessation; Magnus Neuromodulation System with SAINT Technology has 510(k) clearance for MDD in adults with inadequate antidepressant response. The policy also lists TMS device capabilities (e.g., H‑coil depth up to ~6 cm versus ~2 cm for figure‑8 coils) and summarizes reported device‑related adverse events (headache, facial or tooth pain, neck pain, rare seizures).

The policy contains an extensive, indication‑by‑indication literature review summarizing where TMS evidence is insufficient or not FDA‑approved. It lists numerous conditions for which TMS has not been proven effective in peer‑reviewed literature or lacks regulatory approval, including addictions, Alzheimer disease, ALS, eating disorders, many anxiety and psychotic disorders, pain syndromes, movement disorders (Parkinson's, Huntington's, dystonia), epilepsy, stroke and post‑stroke rehabilitation outcomes, tinnitus, and pediatric indications, among others.

For major depressive disorder (MDD), the policy cites multiple randomized trials and meta‑analyses comparing modalities (high‑frequency left DLPFC, low‑frequency right DLPFC, bilateral, TBS, priming, accelerated TMS). Systematic reviews (e.g., Brunoni et al. 2017) found some modalities superior to sham for response/remission but concluded that no single modality has definitive superiority due to imprecision and heterogeneity. The policy documents that some device/technique combinations (e.g., certain TBS and SAINT/accelerated protocols) have FDA clearances/early trial data but underscores limitations: small samples, single‑site studies, and short follow‑up.

The policy examines newer and investigational TMS approaches and their evidence status, describing aTMS (accelerated multiple daily sessions), TBS (theta burst stimulation: intermittent iTBS and continuous cTBS), SAINT/SNT accelerated iTBS protocols, mTMS (multi‑locus electronically steered coils), priming TMS (pTMS), high‑dose TMS, and nTMS for diagnostic/preoperative motor mapping. For most of these methods the document states evidence is limited (pilot studies, small RCTs, or single‑center trials) and safety/efficacy are not established broadly. For example, SAINT protocols have limited RCT and open‑label data from the same institution and are described as having insufficient evidence for durability and generalizability.

For nTMS, the policy notes FDA 510(k) clearance for noninvasive motor cortex mapping (Nexstim eXimia) and summarizes systematic reviews/meta‑analyses suggesting nTMS correlates reasonably with intraoperative direct electrical stimulation and may be associated with higher gross total resection rates and reduced permanent motor deficits in observational studies. However, Cigna characterizes the overall evidence as limited by nonrandomized designs, heterogeneity, and lack of definitive trials demonstrating impact on long‑term health outcomes.

The policy details safety considerations across TMS approaches and documents commonly reported adverse events: transient headache, scalp discomfort, facial/neck pain, tooth pain, lightheadedness, and rare occurrences of seizures and hearing effects. Theta burst protocols are noted to have a potentially higher seizure risk given high‑frequency bursts. The document also emphasizes variability in stimulation parameters (frequency, intensity, pulse number, waveform) as factors affecting both efficacy and safety profiles.

Methodological limitations cited repeatedly include small sample sizes, short‑term follow‑up, heterogeneity of patient populations and TMS protocols, inconsistent outcome measures, and concurrent psychopharmacotherapy in many trials. These limitations underpin the policy's conclusions about where TMS is supported and where evidence remains insufficient.